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Abstract
During recent years, comparative genomic analysis has allowed the identification of Mycobacterium leprae-specific genes
with potential application for the diagnosis of leprosy. In a previous study, 58 synthetic peptides derived from these
sequences were tested for their ability to induce production of IFN-c in PBMC from endemic controls (EC) with unknown
exposure to M. leprae, household contacts of leprosy patients and patients, indicating the potential of these synthetic
peptides for the diagnosis of sub- or preclinical forms of leprosy. In the present study, the patterns of IFN-c release of the
individuals exposed or non-exposed to M. leprae were compared using an Artificial Neural Network algorithm, and the most
promising M. leprae peptides for the identification of exposed people were selected. This subset of M. leprae-specific
peptides allowed the differentiation of groups of individuals from sites hyperendemic for leprosy versus those from areas
with lower level detection rates. A progressive reduction in the IFN-c levels in response to the peptides was seen when
contacts of multibacillary (MB) patients were compared to other less exposed groups, suggesting a down modulation of
IFN-c production with an increase in bacillary load or exposure to M. leprae. The data generated indicate that an IFN-c assay
based on these peptides applied individually or as a pool can be used as a new tool for predicting the magnitude of M.
leprae transmission in a given population.
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Introduction
Leprosy is a chronic infectious disease caused by the obligate
intracellular pathogen Mycobacterium leprae. Multidrug therapy
(MDT), a combination of antibiotics very effective in curing this
mycobacterial infection, was introduced by WHO in the early
eighties. With the success of MDT, in 1991 the World Health
Assembly set a target of eliminating leprosy as a public health
problem by the year 2000. Elimination was defined as reaching
prevalence levels of ,10 case per 100,000 individuals. The
elimination program has been successful in delivering MDT
worldwide, decreasing globally the number of registered cases.
More than 13 million cases were detected and treated with MDT
from 1982 to 2002 [1]. However, the disease is still considered a
public health problem in several countries (www.who.int/lep).
Particularly in Brazil, the new-case detection rate remains high
and stable at approximately 40,000 new cases annually (http://
portal.saude.gov.br) indicating that transmission has not been
adequately interrupted in Brazil by treating leprosy patients with
MDT alone. Therefore new strategies and approaches need to be
developed in order to definitively eradicate leprosy as a public
health problem. This conclusion is supported by recent mathe-
matical modeling of leprosy indicators suggesting that leprosy is
slowly declining but the rate of decline is uncertain, requiring
sustained leprosy control efforts [2].
Leprosy manifests itself as a spectrum of clinical forms, but
which for treatment purposes has been simply divided into
multibacillary (MB) and paucibacillary (PB) leprosy. In Brazil, the
www.plosntds.org 1 April 2012 | Volume 6 | Issue 4 | e1616detection rate among children under 15 years of age is stable and
considered high (approximately 8% of the new cases detected
yearly) indicating that despite a high level of MDT coverage by the
National Leprosy Control Program (PNCH), active transmission
persists (http://portal.saude.gov.br). Leprosy transmission is still
poorly understood. The major sources of the bacteria are
considered to be the multibacillary patients, carrying a high
bacterial load in their skin and being able to shed large numbers of
bacteria from their nasal passages; 10
7 viable M. leprae per day on
average [3]. Two major pitfalls have contributed to our poor
understanding of leprosy transmission: the long incubation period
of the disease estimated to be between 2 and 10 years; and the
absence of a test that could specifically measure exposure to M.
leprae, since the magnitude of the M. leprae-infected population is
much higher than that of individuals with actual leprosy. A
serological test based on the detection of antibodies specific for the
phenolic glycolipid-I (PGL-I) antigen, a unique molecule of the M.
leprae cell wall, is positive in most MB patients but not in PB
individuals, showing a positive correlation with the bacterial load
[4]. New tools that could detect infected/exposed individuals are
desperately needed to measure the level and dynamics of leprosy
transmission. Moreover, most of the infected individuals will never
develop the disease [5]. Thus, a test that could distinguish between
exposed/infected individuals and those evolving to active disease,
should allow for early diagnosis and subsequent prevention of
disabilities as well as stoppage of the transmission chain.
Mycobacteria are intracellular pathogens and as such elicit in
the host a specific cell-mediated immune response that controls the
infection. CD4
+ T helper 1 (Th1) lymphocytes play a central role
in this response, producing IFN-c that will activate the
microbicidal mechanisms of macrophages leading to the killing
of intracellular microorganisms (for a review see [6]). The
protective role of IFN-c has been emphasized in several reports
that describe the deleterious effects on mycobacterial infections of
mutations/deletions in the IFN-c gene and its receptor [7]. Thus,
assessment of T cell functions provides a good alternative
approach for the diagnosis of mycobacterial infections.
In most endemic countries for leprosy, such as Brazil,
tuberculosis is also endemic with 71,641 new cases detected in
2009 (http://portal.saude.gov.br). Moreover, in Brazil, BCG
vaccination is prescribed. Thus, the development of an immuno-
logic test that could specifically detect M. leprae-infected individuals
has to take these facts into account. In this context, a new scenario
was introduced by the genomic era, with the knowledge of whole
chromosome sequences of mycobacterial species, particularly M.
leprae, M. tuberculosis and M. bovis BCG, providing unique
opportunities to identify M. leprae specific antigens. We have used
comparative genome analysis to identify M. leprae-specific genes,
and tested both recombinant proteins and synthetic peptides
derived from a subset of these proteins to test for immunological
reactivity [8–13]. In a previous study performed with individuals
living in Rio de Janeiro, a panel of 58 peptides (15 mers and
9 mers) was tested for induction of IFN-c responses in PBMCs of
leprosy patients, healthy household contacts (HHC) of leprosy
patients, TB patients, and endemic and non-endemic healthy
controls [13]. Encouraging results were generated indicating that
synthetic peptides induce specific responses in individuals exposed
to M. leprae and could potentially be developed into a rapid test for
the detection of M. leprae infection. In the present study, the 17
peptides with the best performance were selected and evaluated in
individuals with different histories of exposure to M. leprae living in
another endemic region of Brazil and in areas that are non-
endemic for leprosy. The data generated indicate that an IFN-c
assay based on these peptides applied individually or as a pool can
be used as a tool for predicting the magnitude of M. leprae
transmission level in a given population.
Materials and Methods
Ethics statement
The tests and procedures described in this work were approved
by the Oswaldo Cruz Foundation and D. Libania Ethics
Committees. All subjects provided informed written consent.
Study population
For the analysis of IFN-c levels induced by M. leprae-derived
peptides, a total of 127 volunteer subjects living in the city of
Fortaleza, Ceara ´ State, Brazil were enrolled. Untreated pauciba-
cillary (PB) (three tuberculoid (TT) and 18 borderline tuberculoid
patients [BT]), and multibacillary (MB) (eight lepromatous [LL]
and thirteen borderline lepromatous patients [BL]) leprosy
patients, household contacts of multibacillary patients (HCMB,
n=37), and household contacts of paucibacillary patients (HCPB,
n=27) were recruited from the Dona Liba ˆnia Reference Center,
Fortaleza, Ceara ´, Brazil. Healthy individuals with no history of
exposure to leprosy and/or tuberculosis were recruited from Bom
Jardim (endemic controls high burden, EChigh, n=20) and
Meireles (endemic controls medium burden, EClow, n=18),
Fortaleza districts with, respectively, hyperendemic (162 cases
per 100 000 inhabitants) and medium (9 cases per 100 000
inhabitants) annual new case detection rates for the disease.
Twenty one healthy blood donors recruited from the Blood Bank
of the Fundac ¸a ˜o Estadual de Pesquisa e Produc ¸a ˜o em Sau ´de,
Porto Alegre, Rio Grande do Sul State, Brazil (non-endemic
controls, Brazil; NECBrazil), and with no history of exposure to
leprosy or tuberculosis were also included. Rio Grande do Sul was
the first Brazilian State to achieve the WHO leprosy elimination
goal in 2001 (a prevalence rate lower than 10 cases per 100,000
inhabitants). The 2009 new case detection rate in this State was
1.44/100,000. This State is, however, endemic for tuberculosis;
with a detection rate of 46.14/100,000 in 2009 (http://portal.
Author Summary
Despite the efforts to treat registered leprosy patients, the
number of new cases reported globally remains stable and
high (about 200,000/year). As the treatment of multi-
bacillary leprosy patients, the major recognized source for
new infections, did not allow the expected reduction in
new leprosy cases, additional sources must be considered.
Following exposure to M. leprae infection, the evolution to
active disease is estimated to take from 2 to 10 years, and
it is conceivable that some of these asymptomatic
individuals could be a yet unrecognized source of
infection. Previously, the use of computational tools
allowed us to select M. leprae-specific genes or gene
regions, and derive M. leprae-specific synthetic peptides
from the M. leprae genome. Ex vivo stimulation of the
blood leukocytes with a subset of these peptides induced
IFN-c production that allowed the differentiation of
individuals exposed to M. leprae from unexposed ones.
Individuals with no known history of exposure to M. leprae,
but living in an area with high frequency of leprosy cases
had high-level positive responses to the peptides. This last
observation raised the possibility of using this test as a tool
for evaluating the level of transmission of M. leprae
infection in areas of interest.
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individuals included in the study are shown in Table 1. Two
additional control groups, pulmonary tuberculosis patients who
had received more than three months of treatment (tuberculosis,
Netherlands; TB; n=8) and healthy donors recruited at the Blood
Bank Sanquin, Leiden, The Netherlands (non-endemic controls,
Netherlands; NECNetherlands; n=8), all residents of the Nether-
lands, a non-endemic country for leprosy, were also included in
the study.
M. leprae whole cell sonicate
Irradiated armadillo-derived M. leprae whole cells were probe
sonicated with a Sanyo sonicator to .95% breakage. This
material was provided through the NIH/NIAID ‘‘Leprosy
Research Support’’ Contract N01 AI-25469 from Colorado State
University (these reagents are now available through the
Biodefense and Emerging Infections Research Resources Repos-
itory listed at http://www.beiresources.org/TBVTRMResearch
Materials/tabid/1431/Default.aspx).
In vitro stimulation of PBMC with antigens
Blood was drawn by venipuncture, heparinized, and PBMC
were isolated using Lymphoprep (Pharmacia Biotech, Uppsala,
Sweden) by density gradient centrifugation, washed in PBS and
resuspended in AIMV medium (Invitrogen, Grand Island, NY,
USA) supplemented with 100 U/ml penicillin, 100 mg/ml strep-
tomycin and 2 mM L-glutamine (Sigma Chemical, St. Louis,
MO). PBMC from each individual were seeded at 2610
5 cells per
well in 96-well round-bottomed plates in duplicate (BD Biosci-
ences, San Jose, CA) and stimulated in vitro with armadillo-derived
M. leprae whole cells (20 mg/ml), PPD (10 mg/ml) individual
peptides (10 mg/ml), Pool 1[p52, p61, p68, p69] (0,1; 1,0 and
10 mg/ml), Pool 2 [p38, p51, p56, p59, p65, p67, p70, p71, p88,
p91, p92] (0,1; 1,0 and 10 mg/ml)or staphylococcal enterotoxinB
(SEB, 1 mg/ml) (Sigma). Cultures were incubated at 37uCi n
humidified 5% CO2 atmosphere. Supernatants were harvested at
day-five of incubation and stored immediately at 270uC.
IFN-c ELISA
IFN-c levels were determined in duplicate by ELISA (U-
CyTech, Utrecht, The Netherlands). The cut-off value to define
positive responses was set beforehand at 100 pg/ml. The assay
sensitivity level was 40 pg/ml. Values for unstimulated cell
cultures were typically ,20 pg/ml [10].
ELISA for detection of anti-PGL-I IgM
ELISA for detection of anti-PGL-I IgM was done as previously
described [15]. The antigen used in ELISA was NT-P-BSA
(synthetic native trisaccharide of PGL-I coupled to BSA through a
3-phenylpropanoyl) [14], and a cutoff value of 0.25, at an optical
density at 450 nm (OD450) was set for positive responses [15].
Statistical analysis
Artificial Neural Networks (ANN) modeling (Statistica Neural
Networks 7, Statsoft, Tulsa, OK, USA) was used for the selection
of peptides with the best performance in discriminating individuals
with M leprae infection/disease based on its capacity to induce IFN-
c production in PBMC. The ANN model used for evaluating the
peptides had 3 layers of neurons (Feedforward neural network). In
the first or input layer, each node receives the IFN-c level values in
response to a given peptide. Each neuron of the first layer is
connected to all the neurons of the second or hidden layer. The
IFN-c levels are multiplied by the weights or synaptic strengths
before entering the neurons of the second layer. The second layer
neurons integrate these processed values and if the resulting
number is above an established threshold, this activates the
delivery of a value to a synapse connecting the second layer
neuron to the single neuron in the output layer. If the sum of the
weighted numbers coming from the hidden layer is below the
threshold of the output neuron, a ‘‘0’’ output is obtained, or if the
value is above the threshold a ‘‘1’’ output is the result. The ‘‘0’’
was associated to one group (Ex. Non-exposed individuals) and the
‘‘1’’ to a second and expectedly different group (Ex. Individuals
exposed/infected with M. leprae). The software trains the ANN by
adjusting the synaptic values using the IFN-c levels of individuals
with known exposure/infection status. The ANN training is
validated by analyzing a second group with no information made
available to the ANN regarding infection status, and finally the
ANN is used for testing with the complete groups to be
differentiated. The performance of each peptide in discriminating
different groups is evaluated by using the performance ratio (PR)
of that peptide, a ratio between the mean square error (MSE) of
the ANN with exclusion of the responses to the peptide (MSEex)
and the MSE of the ANN including the peptide (MSEcomp;
PR=MSEex/MSEcomp). Peptides with the PR values of less than
‘‘1’’ in a given ANN configuration were preferentially removed,
and the performances of the ANN with and without those peptides
compared in order to reach the best set of peptides for the
discrimination of individuals exposed/infected with M. leprae,o r
with active disease.
Levels of IFN-c responses to M. leprae peptides were compared
among groups by Kruskal-Wallys test. Multiple tests were used to
compute post-hoc comparisons for all the pairs of groups. A p
value of 5% or less was considered significant. The analyses were
performed with the STATISTICA software (Statsoft). Box plot
graphs were done using the SPSS software (SPSS Inc, Clicago, IL,
USA).
Results
Selection of M. leprae-specific peptides
In order to identify people infected with M. leprae using an
interferon-c release assay, M. leprae-specific epitopes were required
for ex vivo stimulation of the memory T cells of the individuals
infected with this bacillus. The set of peptides had to be
promiscuous, ideally binding to all the HLAs expressed in the
population to be evaluated, to make sure that absence of IFN-c
detection would happen only in non-exposed people. The in silico
analysis of genomes allowed the selection of M. leprae-specific genes
Table 1. Baseline characteristics of Brazilian patients and
healthy controls.
Group N M/F ratio Age BI mean
Mean 25th 50th 75th
NECBrazil 21 13/8 32,71 7 12 2 -
EClow 18 6/12 34,89 6 11 1 -
EChigh 20 9/11 33,35 5 15 - -
HCPB 27 10/17 29,81 11 15 1 -
HCMB 37 11/26 37,35 10 18 9 -
PB 21 7/14 41,43 3 13 5 0
MB 21 12/9 42,8 4 10 7 2,72
doi:10.1371/journal.pntd.0001616.t001
Identification of M. leprae Infection
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identifying HLA-binding regions to these specific protein sequenc-
es. The chosen regions or epitopes were selected for binding to
class I (9 mers) and class II (15 mers) HLA molecules [13].
Seventeen peptides were selected for this study from the original
panel of 58 M. leprae-specific peptides. These peptides were
previously tested for induction of IFN-c release by PBMC from
leprosy patients and contacts, endemic and non-endemic controls
[13]. The IFN-c levels induced by the peptides in non-exposed
(EClow) and exposed individuals (HCMB) were used for selecting
the best set of peptides allowing discrimination of the M. leprae-
exposed from the non-exposed group, by applying an ANN
algorithm (Figure 1). When the peptides with PRs below 0.96
were removed, a final step of selection by ANN ranked the 12 best
peptides in terms of potential for discriminating M leprae infection/
disease (Table 2). The final 12 peptides made the right choice in
96% of the tested individuals in defining the individual status
regarding infection with M. leprae (Figure 1; Table S1). Five
additional peptides from the original panel of 58 [13] but with PRs
below 0.96 (Table 2) were included in the subsequent analysis.
High-level of leprosy detection rate is associated with
responsiveness to M. leprae specific peptides by
individuals with no history of contact with leprosy
patients
The study population consisted of individuals living in the city of
Fortaleza, Ceara ´ State, located in the Northeast region of Brazil.
Figure 1. Selection of M. leprae-specific peptides. Fifty-eight M. leprae-specific peptides were previously tested for induction of IFN-c release by
PBMC from leprosy patients and contacts, endemic and non-endemic controls [13]. The IFN-c levels induced by the peptides in non-exposed (EClow)
and M. leprae-exposed individuals (HCMB) were used for selecting the best set of peptides allowing discrimination of the exposed group by applying
an ANN algorithm. The final 12- peptide ANN made the right choice in 96% of the tests, identifying M.leprae-exposed or non-exposed individuals. *,
individuals recruited from the city of Rio de Janeiro.
doi:10.1371/journal.pntd.0001616.g001
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of Geography and Statistics, 2009), and divided administratively in
114 districts. Besides the leprosy patients and their household
contacts recruited from the Dona Liba ˆnia Reference Center, two
groups of healthy individuals with no history of previous contact
with leprosy were enrolled in the study. These individuals had
residential addresses in Meireles or Bom Jardim, two districts of
Fortaleza with, respectively, medium (9 cases per 100,000
inhabitants) and hyperendemic leprosy new case detection rates
(160 cases per 100,000 inhabitants).
PBMC from leprosy patient groups (PB and MB), leprosy
household contacts of PB (HCPB) and MB (HCMB) patients,
healthy endemic controls from Meireles (EClow) and from Bom
Jardim (EChigh), healthy controls from Porto Alegre (NECBrazil),
Dutch tuberculosis patients (TB) and Dutch healthy, non-endemic
controls (NECNetherlands) were stimulated with peptides and control
antigens, and IFN-c was measured in culture supernatants on day
5 of incubation. The IFN-c levels in the PBMC cultures of the
different groups stimulated with the seventeen individual peptides
are shown in the Figures 2, 3, 4. IFN-c responses were below or,
in a few cases, just above the detection limit, in all unstimulated
cultures (medium alone) for all groups. All individuals responded
well when their cells were cultured in the presence of the
superantigen SEB (data not shown). Figure 2 A–E shows the
responses of PBMC from groups of healthy individuals living in
areas with different and increasing new case detection rates for
leprosy (from zero to 162/100,000). Most of the Dutch individuals
(TB and NECNetherlands groups) were responsive to PPD, but IFN-
c was below or, in a few cases, just above the detection limit in
response to all M. leprae peptides, indicating absence of cross
reactivity of the M. leprae-specific peptides in patients infected with
M. tuberculosis or in BCG-vaccinated individuals (Figure 2A, 2E).
The other control group enrolled in the study consisted of people
living in Rio Grande do Sul, the first Brazilian State to achieve the
WHO leprosy elimination goal (defined as a prevalence rate of
lower than 10 cases per 100,000 inhabitants) in 2001. As shown in
Figure 2B, most of the members of this group (NECBrazil)
produced undetectable levels of IFN-c for all the peptides. A few
outliers responded to the peptides, but the pattern of the group was
clearly different from the observed in groups from endemic areas.
However, evaluation of the IFN-c responses of individuals living in
Meireles (EClow) and Bom Jardim (EChigh), districts of Fortaleza
with medium and hyperendemic leprosy new case detection rates,
9 and 162 per 100,000 inhabitants, respectively, showed a marked
contrast. Most members of the EClow group displayed a reduced
frequency of positive responses to the peptides. In contrast,
members of the EChigh group showed good responses to all the
peptides; the detection rate for leprosy is 18 times higher in the
Bom Jardim district than in the Meireles district of Fortaleza. The
groups of volunteers from these two sites had no history of known
contact with leprosy patients; so, the levels of IFN-c observed in
the Bom Jardim individuals are consistent with the hypothesis that
above a certain frequency of cases in the population, exposure to
infection reaches the whole population, and history of contact with
a leprosy patient is less relevant as an indicator of exposure to
infection with M. leprae. Figure 3 A–D shows the IFN-c levels
observed in response to the peptides in groups of household
contacts of leprosy patients (HCPB and HCMB). In general, lower
levels of IFN-c were observed in the HCMB group when
compared to the HCPB. As expected, most of the PB patients
responded to all the peptides (Figure 4 A). The same set of
peptides, except for p85, also elicited IFN-c production in MB
leprosy patients although at a lower level (Figure 4 B).
The serum levels of anti-PGL-I IgM were measured in all of the
Brazilian individuals enrolled in the study (Figure 5E). Assuming
a cut off of 0.25, positivity to anti-PGL-I IgM was observed in 80%
MB, 60% PB, 40% HCMB, 25% HCPB, 30% EChigh, 10% EClow
and 10% NECBrazil. An analysis of IFN-c responses in positive vs.
negative individuals showed significant differences in the HCPB
group, with higher levels of IFN-c produced by individuals who
were anti-PGL-I negative (Figure 3C, 3D; differences were
significant at a p,0.05 except for p59 and p85. Kruskal-Wallys
test). No differences of the same kind were observed when PGL-I-
positive and –negative HCMB were compared (Figure S2).
Levels of IFN-c in response to M. leprae-specific peptides
are progressively reduced with increase in exposure to
infection and in bacillary load
In order to link responses of the Brazilian groups of individuals
with increasing exposure to M. leprae and increasing bacillary loads
among the patients, the medians for the IFN-c levels in response to
the M. leprae-specific peptides were plotted simultaneously, and the
resulting graphic shows an initial increase in the IFN-c levels to all
the peptides starting at baseline with the Brazilian non-endemic
group (NECBrazil) and the endemic controls in area of medium
leprosy detection rate (EClow). IFN-c levels peaked in the controls
for hyperendemic areas (EChigh) and contacts of paucibacillary
leprosy patients (HCPB). The remaining groups show a progres-
sive decline in IFN-c levels that can be associated with continuous
exposure to live M. leprae (HCMB) or increasing bacillary load for
the two groups of patients (PB, MB) (Figure 5A). This observation
Table 2. Ranking of selected M. leprae-specific peptides
according to performance ratio in Artificial Neural Network
assessment.
ML number Peptide Sequence Location PR
ML0008c p38* TRLLTVVVKQRSKAF aa21–35 1.36
ML1419c p69* RLDGTTLEV aa113–121 1.31
ML1553 p71* LDIYTTLARDMAAIP aa180–194 1.23
ML1057 p52* QLLGQTADV aa59–67 1.22
ML1419c p68* LLEEGVIVL aa267–275 1.21
ML1057 p51* AAALEQLLGQTADVA aa54–68 1.18
ML1420 p70* MQEYRGLTSHTPCCR aa93–107 1.15
ML0638 p85 NYEVSPIFARWPRNR aa49–63 1.09
ML1419c p65* EAVLLRLDGTTLEVE aa108–122 1.05
ML0398c p59 MLILGLLPAILPACG aa15–29 1.04
ML0398c p61 LILGLLPAI aa16–24 1.02
ML0308 p56 FDEYRAMFALSAMDL aa17–31 0.96
ML2452c p92* LQAYSNLFGRTSAMQ aa28–42 0.91
ML2347 p91* LATVQYDDRRRFTKE aa301–315 0.89
ML1419c p67* SGRVTYLNPVGVKWM aa51–65 0.87
ML1189c p88* DDIWRTLASAVITGN aa55–69 0.86
ML1829 p73* DAEWLKLTSLGLRPR aa108–122 0.85
Peptides (n=17) were ranked according to highest (.1.0, n=11) to lowest
(,1.0, n=6) performance ratio (PR) according to the artificial neural network
(ANN). These peptides were selected from the original set of 58 peptides
analyzed in a previous work [13]. From this study, peptides that gave responses
only in the leprosy patient group and household contacts, but not in the TB or
EC (healthy endemic control) groups appear with an asterisk; bold indicates the
peptide is from a hypothetical unknown protein.
doi:10.1371/journal.pntd.0001616.t002
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www.plosntds.org 5 April 2012 | Volume 6 | Issue 4 | e1616Figure 2. Leprosy detection rates and responsiveness to M. leprae specific peptides. Peripheral blood mononuclear cells (PBMCs) from
individuals with different levels of exposure to M. leprae were stimulated with 17 M.leprae-specific peptides, and the concentration of IFN-c measured
in culture supernatants. The boxes include response rates of 75% of the sample, and the horizontal bars in bold identify the medians. Points outside
the deviation correspond to outliers. #, Values between 1.5 and 3 box lengths from the upper or lower edge of the box. *, Values more than 3 box
lengths from the upper or lower edge of the box. A: A Dutch group of healthy non-endemic controls (NECNetherlands); B: healthy controls from Porto
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unfractionated M. leprae were evaluated (Figure 5B). This initial
elevation and subsequent decline of IFN-c levels in response to M.
leprae was also observed when responses to only HLA class I- and
HLA class II-restricted peptides were plotted (Figure 5C, 5D).
This reduction in IFN-c levels for M. leprae and M. leprae-derived
peptides was not seen in the responses of the same groups to PPD
and SEB (Figure S1; Table S2).
The down modulation of M.leprae-specific IFN-c in the groups
followed an inverse path when compared to the levels of PGL-I-
specific IgM in the same groups (Figure 5E).
The evaluation of statistically significant differences between the
groups can be summarized as follows: No difference was found
when responses to the peptides of the NECBrazil and EClow were
compared. Nine to 16 peptides out of 17 induced markedly higher
levels of response in exposed asymptomatic individuals (EChigh,
HCPB, HCMB) in comparison to the low-exposure or non-
exposed individuals (NECBrazil,E C low). In comparison to the
exposed asymptomatic groups, the patients were responsive to a
reduced number of peptides, but even the MB patients had
responses that could be differentiated from the NECBrazil and/or
EC low to 4 peptides (p56, p69, p71, p91). Another aspect that
Alegre, Brazil (NECBrazi); C: healthy endemic controls from an area with medium annual new case detection rate for leprosy (Meireles, Fortaleza, CE,
Brazil; EClow); D: another area with hyperendemic leprosy annual new case detection rate (Bom Jardim, Fortaleza, CE, Brazil; EChigh); E: a Dutch group
of tuberculosis patients (TB).
doi:10.1371/journal.pntd.0001616.g002
Figure 3. Responsiveness to M. leprae-specific peptides in household contacts of leprosy patients. The ex vivo stimulation of PBMC was
done as described in Fig. 2 legend. A: Household contacts of paucibacillary (HCPB); and B: multibacillary leprosy patients (HCMB). The responses to
the 17 M. leprae-specific peptides in PGL-I positive and negative HCPB are shown in separate plots (C,D). Detection of IgM anti-PGL1 in sera was
performed using a specific ELISA.
doi:10.1371/journal.pntd.0001616.g003
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response in the MB patients in comparison to the exposed
asymptomatic individuals (Kruskal-Wallys test, Table S2).
Increase in the threshold for inducing IFN-c production
in response to pools of M. leprae-specific peptides is
observed with increase in exposure to M. leprae or active
disease
The use of pools of class I and class II-restricted M. leprae-
specific peptides is a necessary step towards a more simplified test.
For evaluating the responses to the pools, groups expected to
display different levels of response to M.leprae were tested: healthy
controls from the hyperendemic area (Bom Jardim; EChigh), the
medium leprosy detection rate area (Meireles; EClow), household
contacts of MB patients (HCMB), and PB patients (Figure 6). A
second aspect evaluated with the use of peptide pools was the use
of 3 peptide concentrations, in a 0.1 to 10 mg/mL range. The
responses to the class I-restricted peptides (9 mers) were markedly
higher and applied to more individuals when the EClow were
compared to the EChigh. The highest level of stimulation was
required for inducing IFN-c responses in some HCMB and PB
patients. The class II-restricted stimulation induced responsiveness
and peak levels of IFN-c in all the evaluated groups at lower
concentrations than the class I-restricted stimulus. The two pools
of peptides induced responsiveness in more individuals and at
lower doses in the EClow and EChigh than in the HCMB and PB
groups. Taken together the IFN-c responses induced by peptide
pools suggest that the threshold for M. leprae-specific production of
IFN-c increases with increased exposure to M. leprae, providing a
potential explanation for the decline in M. leprae-specific IFN
production observed with increased exposure to M. leprae (HCMB)
or active disease (PB).
Discussion
Humans constitute the only known reservoir of M. leprae, except
in those select areas with zoonotic leprosy in armadillo populations
[16]. It is generally assumed that all diseased individuals must have
contracted leprosy directly or indirectly from another infected
person. However, the inability to recognize subclinical or latent
infections in association with the long incubation time have
hampered our knowledge about the mode and source of M. leprae
transmission and the risk factors associated with disease manifes-
tation among infected individuals. In the previous [13] and present
study, we showed that a set of M. leprae MHC class I and class II-
restricted peptides can specifically identify individuals exposed to
M. leprae infection and with active disease. The set of M. leprae-
specific peptides clearly differentiated individuals from an endemic
area (Fortaleza) from those living in a non-endemic site for leprosy
in Brazil, but with endemic tuberculosis (Porto Alegre).
Our previous [13] and present studies were conducted in
distinct endemic sites of Brazil (Rio de Janeiro and Fortaleza),
suggesting that despite differences in genetic background, a very
similar combination of peptides could efficiently discriminate
between exposed and unexposed individuals in other endemic
countries. We propose as a major application for this test its use as
an epidemiological tool by National Leprosy Control Programs, to
define the magnitude of the infected population and consequently
of transmission in an endemic area for leprosy. Currently a
calibration curve of leprosy new case detection rate versus IFN-c
levels is under construction by evaluating sites with increasing
annual leprosy new case detection rates. In addition these peptides
are also being analyzed in other leprosy endemic areas in Ethiopia
and Asia in order to estimate their use on a worldwide basis.
As a positive response to PGL-I, a specific marker of M. leprae is
an indicator of bacillary load, the combination of these two
observations pointed to a role for M. leprae or M. leprae components
in negatively modulating IFN-c production in infected individuals,
and perhaps contributing to the evolution from infection to active
disease in M. leprae-exposed individuals.
These observations were combined to elaborate a model
relating IFN-c production with the initially asymptomatic M.
leprae infection, and as the infection progresses to disease, a down
regulation of M. leprae-specific IFN-c production (Figure 7). The
relative IFN-c levels of the different groups were derived from the
median values shown in Figure 5A. This observation suggested a
new role for the continuous exposure to live M. leprae seen in
contacts of multibacillary leprosy patients, not only allowing M.
Figure 4. Responsiveness to M. leprae-specific peptides in PB and MB leprosy patients. The ex vivo stimulation of PBMC was done as
described in Fig. 2 legend. A: Paucibacillary (PB); and B: multibacillary (MB) leprosy patients.
doi:10.1371/journal.pntd.0001616.g004
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www.plosntds.org 8 April 2012 | Volume 6 | Issue 4 | e1616Figure 5. Level of exposure to M. leprae and response to the bacillus or M. leprae-specific peptides. Medians of the IFN-c levels induced
by M.leprae-specific peptides (A, C, D) or sonicated M. leprae (B) are shown for groups displayed in increasing order of exposure to M. leprae from left
to right in the ‘‘x’’ axis. Detection of IgM anti-PGL1 in sera was performed using a specific ELISA (E).
doi:10.1371/journal.pntd.0001616.g005
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immune response to this bacillus, available from an exogenous
source in the HCMB, or an endogenous source for the PB and MB
patients. The distribution of groups in Figure 7 also raised the
possibility that if we want to evaluate immune response in the
asymptomatic phase of M. leprae infection, patients are not the best
option for positive responses. Of note, a similar graph was
generated based on the production of IFN-c in response to the
whole bacteria (Figure 4B; except for groups living in sites with
low/medium prevalence rates in which a higher background is
seen with whole bacteria probably due to cross reactivity),
indicating that the immune response to the peptides follows a
similar trend as to the whole bacterium.
The proposed model associated the NECBrazil and EClow groups
as the individuals with no or reduced exposure to M. leprae
infection. A second group can include healthy controls from high
endemicity areas (EChigh) and contacts of PB patients (HCPB).
The HCMB group already had intermediate values for IFN-c, and
the patients were at the lower end among the groups of infected
individuals. So we tested by ANN the possibility of discriminating
infected individuals from patients. The group combining EChigh
and HCBP was evaluated against MB and PB patients and the
decline in IFN-c levels allowed the correct discrimination of
patients in 84.21% of the cases.
A very interesting observation among the groups of non-contact
healthy individuals was the correlation between the levels of IFN-c
Figure 6. IFN-c production in response to pools of M. leprae-specific peptides. PBMCs from PB (A), HCMB (B), EChigh (C) and EClow (D)
groups stimulated with the 9 mer peptide pool (p52, p61, p68, p69 – 0.1, 1.0 and 10 mg/mL) and the 15 mer peptide pool(p38, p51, p56, p59, p65,
p67, p70, p71, p88, p91, p92 - 0.1, 1.0 and 10 mg/ml). After 5 days culture, supernatants were harvested and assessed for levels of IFN-c by ELISA. Each
circle indicates an individual and the dash the median.
doi:10.1371/journal.pntd.0001616.g006
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While the IFN-c levels were (almost) absent in individuals living in
areas with low/medium prevalence rates (NECBrazil and EClow
groups), in residents of high-prevalence neighborhoods of
Fortaleza (EChigh group), levels were comparable to those seen
in household contacts of leprosy patients. These data indicate that
in areas with high prevalence rates, the exposure to M. leprae is
independent of a previous history of contact with leprosy patients.
These results are in agreement with previous studies indicating
widespread M. leprae nasal carriage as determined by PCR among
the general population in an area in which leprosy is endemic [17].
Moreover, they support the view that prolonged intimate contact
with a leprosy patient is not required for transmission as has been
shown in studies on medical personnel [5], and may explain why a
good proportion of incident cases arise among individuals with no
previous history of contact with leprosy [18,19]. Our data also
support the general view that M. leprae is highly infectious but
poorly pathogenic and that most individuals exposed to M.leprae
present a subclinical infection and develop a protective immune
response against this bacillus.
Although close contact is not critical for infection, it seems to
play a key role in leprosy manifestation. The critical role of IFN-c
in controlling M. leprae infection was first described by Nogueira
et al. [20] who demonstrated that lepromatous leprosy and
borderline lepromatous patients, in deep contrast to tuberculoid
patients, failed to release this cytokine in response to specific
antigen. In our study, as shown in Figure 5 and 6, the peak of IFN-
c median production was observed in household contacts of
paucibacillary patients (HCPB). Starting from this group, the IFN-
c levels in response to M. leprae or M. leprae-specific peptides is
progressively reduced when groups of increasing levels of exposure
to M. leprae are compared (HCMB), and are further diminished in
leprosy patients. The relatively lower response of contacts of
multibacillary patients in comparison to contacts of paucibacillary
patients suggests that the evolution of latent infection to active
disease is associated with progressive reduction in pathogen-
specific IFN-c production, perhaps in parallel with increase in
bacillary load. This down modulation of effector response to M.
leprae (Ex. IFN-c levels) in consequence of long-term and constant
stimulation of the immune system by the exogenous bacillus
released by the index case is a possible explanation for the well-
known increased risk of household contacts of multibacillary
leprosy patients to develop leprosy [18,21]. Indeed, the observa-
tion that ‘‘super exposure’’ to M. leprae can lead to a decrease in
host resistance was first described in 1973 [5]. In this study, the
authors used a lymphocyte transformation test to show that
contacts of lepromatous patients with active disease displayed
lower in vitro responses to M. leprae when compared with contacts
of lepromatous patients treated for more than six months.
Interestingly, HCPB with positive serology to PGL-I produced
significantly lower levels of IFN-c in response to M. leprae-specific
peptides when compared to PGL-I negative individuals. No
similar influence of levels of anti-PGL-I antibody was observed
among HCMB, may be because in this case the IFN-c levels were
already down modulated due to the high bacterial exposure. The
level of anti-PGL-1 antibody has been considered as a reliable
marker of bacterial load in leprosy patients; anti-PGL-1 levels are
associated with the disease spectrum and decline upon treatment
(for a review see Oskam et al. [4], 2003). Moreover, a higher risk of
developing leprosy has been found among household contacts
seropositive to anti-PGL1 [22]. Thus, PGL-I serology in
association with IFN-c levels in response to the peptides may
constitute a robust test for detecting infected individuals with
higher bacterial loads and more risk of developing leprosy. The
combination of tests for PGL-I specific antibodies and IFN-c in
response to M. leprae-specific peptides may require a follow-up
study for evaluating patterns of response associated with evolution
to active disease or protection. This is currently under investiga-
tion at various endemic sites (Geluk et al., for IDEAL consortium).
The studies on the immune response and models of leprosy
pathogenesis have been concentrated in active cases that constitute
less than 1% of the infected population. Some observations point
to the inhibition of dendritic cell maturation and the low frequency
of DC s in the lepromatous leprosy lesions as examples of the
negative modulation of M. leprae-specific immune response in
leprosy [23]. But, as seen in our observations in contacts of MB
patients and endemic controls of hyperendemic areas, prior to
active disease, PBMC from M. leprae-exposed individuals respond
to M. leprae-specific stimuli with high IFN-c levels. So, at least
initially, priming to M. leprae and differentiation of a Th1 T cell
Figure 7. A model for modulation of IFN-c production during asymptomatic M. leprae infection and active disease.
doi:10.1371/journal.pntd.0001616.g007
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Th1 differentiation of M. leprae can be a possible mechanism for
lower levels of response in HCMB and patients, especially if
components of M. leprae such as PGL-I are the culprits [24]. In the
course of the chronic stimulation of Th1 and other T cell subsets
seen in human and murine diseases such as visceral leishmaniasis,
there is induction of IL-10 production by the IFN-c producing T
cell and subsequent down regulation of Th1 differentiation
[25,26]. This is a mechanism that could be relevant for the
modulation of response in M. leprae latent infection, with potential
relevance for the development of a prognostic test and/or vaccines
for leprosy.
Supporting Information
Figure S1 IFN-c production in response to PPD or SEB.
The ex vivo stimulation of PBMC was done as described in Fig. 2
legend. Medians of the IFN-c levels induced by PPD (A) or SEB
(B) are shown for groups displayed in increasing order of exposure
to M. leprae from left to right in the ‘‘x’’ axis.
(TIF)
Figure S2 Responsiveness to M. leprae-specific peptides
in household contacts of multibacillary leprosy patients
(HCMB). IFN-c levels in response to the 17 M. leprae-specific
peptides of PGL-I-positive and PGL-I-negative HCMB are shown
in plots A and B. Detection of IgM anti-PGL1 in sera was
performed using a specific ELISA (No significative differences at a
p,0.05 level were seen between the PGL-I-positive and negative
individuals. Kruskal-Wallys test).
(TIF)
Table S1 M. leprae peptides predicted to have high binding
scores to HLA molecules.
(DOC)
Table S2 Kruskal-Wallys 2-tailed test, p values.
(DOC)
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